Incidence, paris classification and follow-up in a nationwide, incident cohort of pediatric patients with inflammatory bowel disease by Müller, Katalin Eszter et al.
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print 
DOI : 10.1097/MPG.0b013e31829f7d8c 
 
Incidence, Paris Classification, and Follow-up in a Nationwide  
Incident Cohort of Pediatric Patients With Inflammatory Bowel Disease 
 
Katalin E. Müller, MD, Péter L. Lakatos, MD, PhD, András Arató, D.Sc., PhD, Judit B. Kovács, 
MD, PhD, Ágnes Várkonyi, MD, PhD, Dániel Szűcs, MD, Erzsébet Szakos, MD, PhD, Enikő 
Sólyom, MD, PhD, Márta Kovács, MD, PhD, Marianne Polgár, MD, PhD, Éva Nemes, MD, PhD, 
Ildikó Guthy, MD, István Tokodi, MD, Gergely Tóth, MD, PhD, Ágnes Horváth, MD, András 
Tárnok, MD, PhD, Noémi Csoszánszki, MD, Márta Balogh, MD, Noémi Vass, MD, Piroska Bódi, 
MD, Antal Dezsőfi, MD, PhD, László Gárdos, MD, PhD, Éva Micskey, MD, PhD, Mária Papp, MD, 
PhD, Áron Cseh, MD, PhD, Dolóresz Szabó, MD, Péter Vörös MD, Hungarian IBD Registry Group 
(HUPIR), and Gabor Veres, MD, PhD* 
 
PRIMARY AUTHORS’ AFFILIATIONS: 
Katalin E. Müller, András Arató, Antal Dezsőfi, Dolóresz Szabó, Áron Cseh, Péter Vörös, and 
Gabor Veres, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary 
Peter L. Lakatos, 1st Department of Medicine, Semmelweis University, Budapest, Hungary 
Judit B. Kovács, Marianne Polgár, Heim-Madarász Hospital, Budapest, Hungary 
Ágnes Várkonyi, Dániel Szűcs, Noémi Vass, Department of Pediatrics, Szent-Györgyi Albert 
University, Szeged, Hungary 
Erzsébet Szakos, Enikő Sólyom, BAZ County Hospital, Miskolc, Hungary 
Márta Kovács, Petz County Hospital, Győr, Hungary 
Éva Nemes, Department of Pediatrics, Medical and Health Science Center, University of Debrecen, 
Debrecen, Hungary 
Ildikó Guthy, Jósa Hospital, Nyíregyháza, Hungary 
István Tokodi, Szt. György Hospital, Székesfehérvár, Hungary 
Gergely Tóth, Department of Pediatrics, University of Pécs, Pécs, Hungary 
Ágnes Horváth, Csolnoky Hospital, Veszprém; 8200, Hungary, 
András Tárnok, Department of Paediatric Gastroenterology, The Great North Children’s Hospital, Royal 
Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK, 
Noémi Csoszánszki, 2nd Department of Pediatrics, Semmelweis University, Budapest, 1094, Hungary 
                                                 
 
 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
Márta Balogh, Markusovszky Hospital, Szombathely, 9700, Hungary 
Piroska Bódi, Pándy Hospital, Gyula, 5700, Hungary 
László Gárdos, County Hospital, Zalaegerszeg, 8901, Hungary 
Éva Micskey, Budai Children’s Hospital, Budapest, 1023, Hungary 
Mária Papp, 2nd Department of Medicine, University of Debrecen, Debrecen, 4032, Hungary 
 
HUPIR MEMBERS’ NAMES/AFFILIATIONS: 
Hungarian IBD Registry Group (HUPIR) members: Ildikó Kis, MD, Szt. Borbála Hospital, 
Tatabánya, Hungary; Éva Pollák, MD, Magyar Hospital, Ajka, Hungary; Ildikó Rosta, MD, Schweitzer 
Hospital, Hatvan, Hungary; Károly Schultz, MD, and Ferenc Harangi, MD, Balassa Hospital, 
Szekszárd, Hungary; Katalin Szabados, MD, Hetényi Hospital, Szolnok, Hungary; Erzsébet Szathmári, 
MD, Kenézy Hospital, Debrecen, Hungary; Judit Czelecz, MD, and Katalin Szigeti, MD, Bethesda 
Children’s Hospital, Budapest, Hungary; Katalin Tamás, MD, Budapest, Hungary; András Tóth, MD, 
Szt. László Hospital, Budapest, Hungary; Éva Vajdovich, MD, Bugyi Hospital, Szentes, Hungary; 
Gabriella Tomcsa, MD, Jósa Hospital, Nyíregyháza, Hungary; Erika Tomsits, MD, PhD, 2nd 
Department of Pediatrics, Semmelweis University, Budapest, Hungary; Kriszta Molnár, MD, PhD, 1st 
Department of Pediatrics, Semmelweis University, Budapest, Hungary; Petra A. Golovics, MD, 1st 
Department of Medicine, Semmelweis University, Budapest, Hungary; and Barbara D. Lovász, MD, 1st 
Department of Medicine, Semmelweis University, Budapest, Hungary. 
 
Correspondence:  
Gábor Veres, MD, PhD,  
1st Department of Pediatrics, Semmelweis University,  
53 Bókay Street, 1083 Budapest, Hungary,  
E-mail: veres.gabor@med.semmelweis-univ.hu 
Telephone: 0036-20-8258163  Fax:+ 36-1-3036077 
Supportive foundations: 
Gabor Veres is holder of the János Bolyai Research grant; this article was supported by the János 
Bolyai Research and Scholarship of the Hungarian Academy of Sciences (OTKA-K 105530). 
 
Word count: 19267 
Number of figures: 2 
Number of tables: 4 
 
The authors report no conflicts of interest 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
 
Abstract  
 
Objectives: Our aim was to evaluate the incidence, baseline disease characteristics, and disease 
location based on Paris Classification in pediatric inflammatory bowel disease (IBD) in the 
Hungarian nationwide inception cohort. In addition, one-year follow-up with therapy was 
analyzed also. 
Methods: From January 1, 2007 to December 31, 2009, newly diagnosed pediatric patients with 
inflammatory bowel disease were prospectively registered. Twenty-seven pediatric 
gastroenterology centers participated in the data collection ensuring the data from the whole 
country. Newly diagnosed patients with IBD younger than 18 years were reported. Disease 
location was classified according to Paris Classification. 
Results: A total of 420 patients were identified. The incidence rate of pediatric inflammatory 
bowel disease was 7.48/105 (95% CI 6.34/105-8.83/105). The incidence for Crohn’s disease (CD) 
was 4.72/105 (95% CI 3.82-5.79), for ulcerative colitis (UC) 2.32/105 (95% CI 1.71-3.09), and for 
IBD-unclassified (IBD-U) 0.45/105 (95% CI 0.22-0.84). Most common location in CD was L3 
(58.7%); typical upper gastrointestinal abnormalities (ulcer, erosion and aphthous lesion) were 
observed in 29.9%. Extensive colitis in UC patients (E4, proximal to hepatic flexure) was the 
most common disease phenotype (57%), while only 5% of children had proctitis. 18.6% of 
patients had ever severe disease (S1). Frequency of azathioprine administration at diagnosis was 
29.5% in CD patients, and this rate increased to 54.6% (130/238) at one year follow-up. In UC 
only 3.3% received azathioprine initially, and this rate elevated to 22.5% (25/111). Use of 
corticosteroid decreased from 50% to 15.3% in patients with UC. Rate of bowel resection in CD 
patients during the first year of follow-up was 5%. 
Conclusions: The incidence of pediatric inflammatory bowel disease in Hungary was among the 
higher range reported. This is the first large, nation-wide incident cohort analyzed according to 
Paris classification which is a useful tool to determine the characteristic pediatric CD phenotype. 
 
Keywords: pediatric inflammatory bowel disease; Crohn’s disease; ulcerative colitis; 
epidemiology; therapy 
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Introduction  
Increasing numbers of pediatric and adolescent patients with Crohn’s disease (CD) and 
ulcerative colitis (UC) have been reported. It is estimated that 15-25% of patients experience the 
onset of their symptoms under 20 years of age (1). In addition, reports have shown an increasing 
incidence of pediatric CD in the last decades (from 1.3-2.3 to 3.1-4.2/105), whereas the incidence 
of UC has remained stable (range: 0.1-0.7/105) (2,3). On the other hand, a recent study has shown 
that this phenomenon is not caused by a trend towards disease onset at a younger age, but this 
may rather be a consequence of the overall increasing incidence of chronic inflammatory bowel 
disease (IBD) (4).  
Data from epidemiological pediatric IBD studies have shown special features unique to 
pediatric IBD, including disease location. With a specific focus on facilitating research an 
international group of IBD experts developed a new classification, the Paris Classification (5), 
which reflects currently available evidence and clinical practice of pediatric IBD. Important 
modifications include classifying age at diagnosis as A1a (0 to <10 years), A1b (10 to <17 years), 
A2 (17 to 40 years) and A3 (>40 years). Furthermore, upper GI (gastrointestinal) involvement 
proximal to ligament of Treitz (L4a) has been distinguished from upper GI involvement distal to 
ligament of Treitz (L4b). The new criteria system allows for classifying both stenosing and 
penetrating disease in the same patient (B2B3), and denoting the presence of growth failure in the 
patient at any time as G1 versus G0. In ulcerative colitis E4 indicates extent of the disease 
proximal to the hepatic flexure, and S1 designates ever severe ulcerative colitis during disease 
course. 
Data on clinical course of pediatric IBD is scarce. There are only few population-based, 
short-term follow-up studies that involved medical and surgical management (6,7,8,9). Eleven to 
44% of CD patients had undergone intestinal resection and total colectomy rate was 17.6% to 
24% of children with UC (7,9). Of note, the prevalence of AZA use was as high as 25% at the 
end of the one-year follow-up. Moreover, an increasing use of immunomodulators and decreasing 
1-year surgery rates in pediatric patients with IBD were observed in a 12 year-prospective 
population-based cohort study from Eastern Denmark 2007-2009 (10).  
Despite the increasing number of epidemiological studies conducted in pediatric IBD, 
there are only few reports available from Eastern Europe, and to our knowledge no nationwide 
study investigated the early disease course. Therefore, our aim was to determine the incidence of 
pediatric IBD in Hungary in a prospective nationwide epidemiological study and to evaluate 
disease location according to Paris Classification.  
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Materials and Methods 
On behalf of the Hungarian Pediatric Gastroenterology Society, a prospective registry of pediatric 
inflammatory bowel disease was launched on the 1st of January, 2007. Cooperation of 27 
institutes has ensured the coverage of the whole country (HUPIR, Hungarian Pediatric IBD 
Registry). The participating institutes include all 4 academic (university) centers in Hungary, 17 
tertiary hospitals, where pediatric gastroenterology is present, 4 secondary hospitals with 
pediatric gastroenterologists, and 2 pediatric gastroenterology outpatient offices. Private pediatric 
gastroenterology offices with endoscopy are not available in Hungary. Furthermore, coordinators 
are in contact with the main adult IBD centers to find adolescents diagnosed in adult centers. We 
contacted regularly the centers via email or phone calls (every months). The coordinators 
contacted the gastroenterologist if there had been any discrepancies in the survey (e.g. confirm 
the proper diagnosis of IBD; discuss the discrepancies between macroscopic and microscopic 
endoscopic findings etc.).  
Questionnaires are filled out by gastroenterologists who made the IBD diagnosis. Newly 
diagnosed IBD patients younger than 18 years are reported. Exclusion criteria were: age at 
diagnosis older than 18 years, missing information on ileocolonoscopy and ileocolonic histology, 
and a diagnostic workup without endoscopic, histologic, and radiologic abnormalities. We 
contacted regularly the centers via email or phone calls (every month). The questionnaires are 
collected via email and original data were validated by the KEM and GV. The coordinator 
contacts the gastroenterologist if there is any discrepancies in the survey (e.g. confirm the proper 
diagnosis of IBD; discuss the discrepancies between macroscopic and microscopic endoscopic 
findings etc.). If data had been still lacking (no time to fulfill the questionnaire), we visited the 
centers and personally collected data from medical records. We also organized personal meetings 
to discuss difficult cases, mostly IBD-U patients. 
We analyzed the data of patients recorded from the 1st of January 2007 to 31st of 
December 2009 (36 months). Age, gender, weight, height, presenting symptoms, concomitant 
diseases, extraintestinal manifestations (EIM), familiarity (first-degree) and complications were 
recorded. Furthermore, characteristics of diagnostic procedures including endoscopy, radiology, 
histology, surgical interventions, and were documented. The survey obtained the data 
anonymously.  
The diagnosis of IBD was based on the Porto criteria, though, EGD and SBFT were not 
always performed despite the recommendation (11). Every child was re-evaluated 12 months 
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following the diagnosis. Physicians had to confirm the diagnosis and report the applied therapy, 
as well as surgical interventions at one-year follow-up.  
Location and phenotype of disease were based on the Paris classification criteria (5). The 
site of the disease was evaluated only for those patients who underwent a complete bowel 
investigation (colonoscopy and esophagogastroduodenoscopy and/or small and large bowel were 
visualized for CD; large bowel was visualized up to the cecum for UC).  
The therapeutic strategy in pediatric IBD in Hungary was based on international 
guidelines. Available therapies at diagnosis for induction of remission include corticosteroids, 
exclusive enteral nutrition, sulfasalazine or mesalazine, antibiotics and for maintenance 
azathioprine. Calcineurin inhibitors or methotrexate are used as a second-line immunosuppressive 
therapies. Infliximab has been available for children with CD in Hungary since 2007.  It is used 
for both induction and maintenance (PCDAI>30, despite immunosuppression therapy for 
minimum 3 months). Indications for surgery included intractable disease, perianal disease, and 
complications of intestinal disease, such as abscess, stricture, intestinal obstruction, and 
intraabdominal fistulas. 
The age- and gender-specific demographical data for calculating incidence were obtained 
from the Hungarian Central Statistical Office. The population, a total of 10.04 million, is 
predominantly white in Hungary. In 2007, 1.8 million of the inhabitants were <18 years old. 
Height, weight and BMI (body mass index) results were converted into standard deviation z 
scores using nomogram of the Hungarian Longitudinal Survey of Children’s Growth. Impaired 
growth was defined as z score lower than -2.  
The study was approved by the National Ethical Committee. 
 
Statistics  
Normality of the data was tested by Kolmogorov-Smirnov tests. Data are expressed mean (±SD) 
and for statistical analyses parametric tests were used. Univariate comparisons were among 
different subgroups (type of diagnosis, genders, extraintestinal manifestation, familiarity, initial 
therapy) with regard to disease phenotype, anthropometrical data. We used Fisher’s exact tests or 
Khi2 tests to compare binominal variables, while t-test with separate variance estimates was used 
to compare continuous variables. To assess the correlation of two parameters in case of 
dichotomous and continuous outcomes, logistic and linear regression models were used, 
respectively. Kaplan–Meier survival curves were plotted to analyze need for surgery. A p<0.05 
was considered as significant. Statistical analyses were performed using the SPSS® statistical 
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package, version 15.0 (SPSS Inc., Chicago, IL, USA) for Windows®. Kaplan-Meier analysis was 
calculated by StatsDirect, version 2,7,8. 
 
Results 
 
Incidence of newly diagnosed pediatric IBD in Hungary  
A total of 420 children with IBD were diagnosed between January 1, 2007 and December 
31, 2009 in Hungary. Twice as many CD cases were registered as UC cases; CD, 265 patients 
(63%), UC, 130 patients (31%); and 25 patients (6%) inflammatory bowel disease type 
unclassified (IBD-U). The clinical characteristics of patients are presented in Table 1. 
The overall incidence of IBD was 7.48/105 per year (95% CI 6.34-8.83) in children <18 
years. The incidence of CD was 4.72/105 per year (95% CI 3.82-5.79), in UC, 2.32/105 (95% CI 
1.71-3.09), and in IBD-U, 0.45/105 per year (95% CI 0.22-0.84). There was no significant 
difference in incidence rate in the three following years (data not shown). 
A male predominance was observed in all patients with CD (male:female ratio 1.43:1), in 
contrast we found a slight female predominance in UC (1:1.15) (Table 1). Mean age was 
12.9±3.47 years for all IBD patients; 12.7±3.51 years in UC, 13.2±3.54 years in CD, and 
12.7±4.28 years in IBD-U (Table 1). Figure 1 shows the age-specific incidence of IBD.  
 
Clinical presentation at diagnosis  
Anthropometry  
Height z score lower than -2SD was reported in 6.5% of patients with CD while only in 0.8% of 
children with UC. Mean z score of BMI was significantly lower in CD than in UC (-0.64 vs. -
0.26, p=0.005). Growth retardation in UC was less severe by increasing age (r=-0.296, p=0.013). 
Gender distribution and normal growth were comparable in CD and UC. 
There was no association between family history, gender, location and growth failure. 
 
Paris Classification  
Most CD patients belonged to the age-group A1b (n=197, 74.3%). Thirteen percent of the 
patients (33/247) showed L1 (involvement of terminal ileum and/or cecum) location (Table 2). 
Isolated colonic disease (L2) was seen in 27.5% (n=68) of children with CD, and ileocolonic 
disease (L3) occurred in 58.7% (n=145) of CD patients. 
Esophagogastroduodenoscopy was performed in 184 (68%) of pediatric CD patients. 
Upper GI was based on macroscopic lesions (erosion, ulcer, aphthous lesion) or on radiological 
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findings (MRI/CT/SBFT). Upper GI abnormality was found in 74 (29.9%) of all children with 
CD, and there was only one patient of 247 (0.4%) with isolated upper GI disease. 
Esophagogastroduodenal involvement (L4a) was present in 30.4% (n= 56) of pediatric CD, while 
L4b (jejunal/proximal ileal) disease occurred in 13.6% (n=25) of children. 
Most CD patients had inflammatory disease at diagnosis (B1+B1p 84.4%), while 12.1% 
CD patients had stricturing disease (B2), 2.3% had fistulizing disease (B3), and 1.2% belonged to 
B2/B3 phenotype. Frequency of perianal disease (abscess, fistula) was 14.5% (37/247). There 
was no significant correlation between gender, phenotype, familiarity, and location. 
Fifty-seven percent of UC patients had disease location E4, and 13 of 121 children have 
ever had severe disease (S1) at diagnosis (Table 3). Disease location did not differ neither by age 
at diagnosis nor by sex. Familiarity, anthropometrical parameters did not show any association 
with location either in CD or in UC.  
 
Extraintestinal manifestation  
EIMs were present in 10.9% of IBD patients at the time of the diagnosis (Table 1). It was more 
common in patients with CD than in children with UC (12.9% vs. 7%), though the difference was 
not statistically significant. The most common EIM was joint involvement (42.5%), followed by 
cutaneous manifestations (31.9%). Multiple EIM was observed in 10.6% of patients with EIM. 
There were no associations between gender, age, family history and EIM.   
 
Therapy at diagnosis and after one year follow-up 
Medical therapy  
Onehundredseventy-seven CD patients (177/259, 68.3%) were treated with systemic 
corticosteroid as initial therapy (Table 4). 19.3% (46/238) of patients received corticosteroid at 
one-year follow-up. Azathioprine was started directly after diagnosis in 32.8% (85/259) of 
children with CD (42.5% within 3 months after diagnosis), and in 54.6% (130/238) at one-year 
follow-up. Infliximab was administered in 14% (33/238) of CD patients after one year of 
diagnosis. Exclusive enteral nutrition was applied in 6 CD patients. 
In UC, the rate of corticosteroid use was 50% (62/124) at diagnosis, and it decreased to 15.3% 
(17/111) at one-year follow-up. Immunomodulator as an initial therapy was reported in only four 
patients (3.2%, 4/124) and 22.5% (25/111) received azathioprine after one year. Infliximab was 
not available in pediatric UC during this period. 
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Surgery 
In CD, the need for surgery for any indication was 11.3% (27/238) within one year from 
diagnosis. Surgical intervention was performed due to perianal abscess in ten cases, three 
fistulectomies occurred, and appendectomy related to diagnosis happened in two cases.   
Cumulative incidence of intestinal resection (small bowel resection or/with partial colectomy) 
was 5.04% (12/238) at one year. Intestinal resection within the first 3 months after diagnosis was 
performed in seven cases. One patient with IBD-U (1/19) had an operation due to perianal 
abscess. There was no need for surgical intervention in 111 patients with UC during the first year 
of the disease course.  
 
 
Discussion 
The present study is the first prospective nationwide cohort - based on Paris Classification - 
reporting on the incidence and management in the first year after the diagnosis in pediatric IBD.  
The incidence rate (7.5/105 per year) of pediatric IBD in Hungary is comparable to that 
reported from high incidence areas (Wisconsin (12), Ontario (13)) within the same age- group 
(under 18 years) (Figure 2). Increasing incidence rates were reported in IBD in the last decades 
in Western Europe in both children and adults (12,14,15). The same trend was reported from 
Eastern European adult studies; however, data on pediatric incidence is limited. According to a 
population-based inception cohort from Veszprem province in Hungary the incidence in adult 
patients has been rising steadily in the last 25 years (incidence 1977-2001: UC: from 1.66 to 
11.01/105per year, in CD from 0.41 to 4.68/105 per year) (16). Even higher incidence rates were 
reported between 2002-2006 (17), similarly to those observed in high incidence Western 
European and Nordic countries.  
Previous studies have suggested a difference in location between pediatric and adult onset 
IBD patients, since pediatric patients have more frequently extensive small- and large bowel 
disease; while the prevalence of limited ileal disease is lower (2.65% vs. 31.5%) (18,19), and 
panenteric disease is more common in children (20). Disease extension in CD (L1, L2, L3) in the 
present study was comparable to disease location in other studies (21,22). Another important 
feature of pediatric CD is the frequent upper GI involvement (30-70%) (21,23). The wide range 
of upper GI abnormality may be explained by the different definition of upper GI disease (any 
abnormalities or specific abnormalities: erosions, aphthous lesions, ulcers at endoscopy) in some 
reports. Diagnostic yield of upper endoscopy was 9% as it was described in details in our recent 
paper (24).  
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Paris Classification was applied in the report of Eurokids Registry (22). Location in CD 
and UC were comparable to the results of the present study.  However, isolated upper GI disease 
was less frequent in our cohort. This discrepancy is probably due to the different population of 
the two studies. Eurokids registry is not a population-based cohort, but a selection of centers with 
special interest in IBD, meanwhile the HUPIR is a population-based incident cohort involving 
less severe cases. This phenomenon emphasize the importance of nation-wide registeries, that 
enrolles all pediatric patients with IBD including less severe cases also.  
In addition, isolated colonic disease was significantly more often in A1a age- group than 
in A1b in Eurokids Registry (22). A similar trend was found in the Hungarian cohort, though the 
difference was not significant. In this population we could not describe any significant difference 
in the subgroups of Paris Classification. The reason for that is probably the small sample size of 
the subgroups, however tendencies were similar to other studies (22). 
Disease behavior has shown to progress during the disease course. Penetrating/stricturing 
phenotype and perianal disease are associated with more aggressive disease course and increased 
risk of surgery. Approximately, one third of newly diagnosed adults presented with complicated 
CD (17). In contrast, the majority of pediatric IBD patients had inflammatory behavior in a 
previous study (91.25%) (20,22), in concordance with figures in the present study (85.3%). The 
rate of perianal disease was comparable with earlier studies (16.9% vs. 14.9%) (22,25).  
Need for surgery is often regarded as the marker of disease severity. Only few pediatric 
studies report the incidence of surgery after one year of diagnosis. The surgical rate (5.04%) in 
our cohort is comparable with the finding of the Pediatric Consortium (6%) (26). It should be 
noted, this is the first nationwide pediatric IBD study where incidence of surgery after one year is 
shown.  
Colectomy among patients with UC was not detected. Similarly, Jakobsen et al described 
no need for surgical intervention in children with UC within the first 2 years after diagnosis (27). 
In contrast, the probability of colectomy in UC was 8% at 1 year, 11% at 2 years, and 20% at five 
years in an earlier study of Gowers-Rousseau et al (9).  
Cumulative probability of surgery after one year in adult CD patients was 10-19% in 
recent reports (17,28). Reduction in surgery rates was reported in population-based adult studies 
in the last 20 years, which is probably due to increasing use of immunomodulation (10). 
Cumulative incidence of surgery during the first year was 15-35% in studies before the era of 
immunomodulators (29,30). The role of immunomodulators in the reduced need for surgery 
during the first year is questionable. In a population-based pediatric cohort (1962-1987), reported 
by Langholz et al, mean yearly operation rate was 13%. In a population-based cohort of children 
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with IBD enrolled between 1984 and 1995 in Sweden, 38 of 639 patients (5.9%) were operated 
within 1 year (31). Interestingly, surgical rates during the first year after diagnosis in pediatric 
population are lower than in adults both in recent and earlier studies. The slight decrease (from 
13% to 4.4-7%) in operation rate in pediatric population in the last decades may be explained as a 
consequence of increased use of azathioprine also (20,21). 
Administration of 5-ASA is high in this CD cohort, however, this phenomenon is not 
restricted to our registry. Initial use of 5-ASA was 95% in a pediatric CD cohort collected 
between 1998-2009 (32). In addition, in a Finnish study 96% of 97 pediatric CD patients still 
used 5-ASA during the first year after diagnosis of CD (33). 
Although we applied a nationwide approach, the study has some limitations. A relatively 
large proportion of the CD patients (62/265) did not have small bowel investigations (CT, MRI, 
SBFT) or EGD, thus upper GI location may be underestimated. The decrease in the incidence in 
the 16-18 year-olds is virtual and associated with the fact that adolescents more frequently tend to 
receive medical care from adult gastroenterologists (40). As a result the incidence in older age-
groups is probably underestimated.  
In summary, the data of our study are remarkable since this is a nationwide incident 
cohort; participants are not only from a few tertiary centers. Important observations of pediatric 
IBD based on the Hungarian Pediatric IBD Registry include (1) incidence of pediatric IBD is 
comparable in Eastern European countries to Western countries, (2) after one year of follow-up 
surgical rate in pediatric patients with CD is 5%, (3) a large population-based cohort has been 
analyzed according to Paris Classification which is a useful tool to determine the characteristic 
pediatric CD phenotype. 
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Figure Legends 
 
Figure 1 Incidence (/105) of pediatric patients with Crohn’s disease, ulcerative colitis and 
inflammatory bowel disease type of unclassified by age-groups (2007-2009). 
 
Figure 2 Incidence of pediatric inflammatory bowel disease (/105) in different geographic area. 
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Figure 2 Incidence of pediatric inflammatory bowel disease (/105) in different geographic 
area. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 
 
Table 1 Demographic characteristics of pediatric patients with inflammatory bowel 
disease diagnosed 2007-2009 in Hungarian Pediatric IBD Registry at diagnosis 
a IBD, inflammatory bowel disease 
bIBD-U, inflammatory bowel disease type of unclassified 
 
 All IBDa 
Ulcerative 
colitis 
Crohn’s 
disease 
IBD-Ub 
Number of patients (%) 420 130 (31.0%) 265 (63.1%) 25 (6.0%) 
Gender     
Male 
227 
(54.0%) 
60 (46.2%) 156 (58.9%) 11 (44%) 
Female 
193 
(46.0%) 
70 (53.8%) 109 (41.1%) 14 (56%) 
Male:Female 1.18:1 1:1.15 1.43:1 1:1.27 
Age     
Mean  
(range, year) 
12.9 
(±3.47) 
12.7 (±3.51) 13.2 (±3.54) 
12.7 
(±4.28) 
Familial disease 41 (10.6%) 12 (10.3%) 25 (10.1%) 4 (18.2%) 
Extraintestinal 
manifestations 
44 (10.6%) 9 (7%) 34 (12.9%) 1 (4%) 
Arthropathy 20 (42.5%) 2 18 0 
Primary sclerosing 
cholangitis 
6 (1.4%) 6 0 0 
Cutaneous 15 (27.6%) 1 14 0 
Ocular 1 (2.1%) 0 1 0 
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Table 2 Disease location and behavior in Crohn’s disease according to Paris 
Classification 
*UGI, upper gastrointestinal involvement 
 
A1a: 0-<10 years, A1b: 10-<17 years, A2:17-<40 years. 
L1: distal 1/3 ileal disease ((±limited cecal disease). L2: colonic disease. L3: ileocolonic disease. L4: 
upper gastrointestinal tract disease. L4a: esophagogastroduodenal disease proximal to ligament of 
Treitz. L4b: distal to ligament of Treitz.  
B1: nonstricturing-nonpenetrating, B2: stricturing, B3: penetrating, B2B3: both penetrating and 
stricturing. 
p: perianal disease modifier 
G1 evidence of growth delay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All CD 
(n=247) 
A1a 
(n=27) 
A1b 
(n=197) 
A2 
(n=23) 
L1 33 (13.4%) 3 26 4 
L1+L4 7 1 6  
L2 68 (27.5%) 9 55 4 
L2+L4 17 2 14 1 
L3 145 (58.7%) 14 116 15 
L3+L4 49 3 40 6 
L4b only 1 (0.4%) 1 0 0 
B1 216 (84.4%) 26 170 20 
B2 31 (12.1%) 1 28 2 
B3 6 (2.3%) 1 4 1 
B2B3 3 (1.2%) - 2 1 
Perianal 
disease 
37 (14.5%) 1 34 2 
G1 (n=244) 16 (6.6%) 3 12 1 
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Table 3 Disease location in ulcerative colitis according to Paris Classification 
E1, ulcerative colitis; E2, left-sided ulcerative colitis (distal to splenic flexure); E3, extensive (splenic 
flexure distally); E4, Pancolitis (proximal to hepatic flexure); S0, never severe; S1, severe at some 
stage. 
 
 
Ulcerative colitis 
(n=121) 
E1 6 (5.0%) 
E2 30 (24.8%) 
E3 16 (13.2%) 
E4 69 (57.0%) 
S0 57 (81.4%) 
S1 13 (18.6%) 
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Table 4 Initial therapy in pediatric patients with inflammatory bowel disease at 
diagnosis. 
*Number of cases with ulcerative colitis at diagnosis 123, number of cases at one year follow-up was 
111. 
** Number of cases with Crohn’s disease at diagnosis was 258, number of cases at one year follow-up 
was 238. 
 
 Initial therapy Therapy at one year follow-up 
Ulcerative colitis*    
5-ASA (oral) 110 (89.4%) 90 (81%) 
Corticosteroid (systemic) 62 (50.4%) 17 (15.3%) 
Azathioprine  4 (3.3%) 25 (22.5%) 
Antibiotics 37 (30%) 1 (0.9%) 
Crohn’s disease**   
5-ASA (oral) 227 (87.9%) 207 (86.9%) 
Corticosteroid (systemic) 177 (68.6%) 46 (19.3%) 
Azathioprine  76 (29.5%) 130 (54.6%) 
Antibiotics 93 (36%) 13 (5.5%) 
 
 
 
 
 
